Table 2. Univariate and multivariate Cox regression analyses predicting biochemical recurrence in the Test-TMA series.
| Parameter | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p-Value | HR (95% CI) | p-Value | |
| Preoperative PSA | 1.06 (1.04–1.09) | <0.001 | 1.03 (1.01–1.05) | 0.007 |
| pT | 4.67 (3.13–6.97) | <0.001 | 2.89 (1.79–4.69) | <0.001 |
| RP Gleason score | 2.03 (1.63–2.54) | <0.001 | 1.65 (1.29–2.09) | <0.001 |
| Margin status | 2.39 (1.52–3.77) | <0.001 | 1.41 (0.87–2.28) | 0.163 |
| Benign adjacent tissue | ||||
| p65 continuous | 1.02 (0.97–1.07) | 0.356 | 1.02 (0.98–1.07) | 0.300 |
| p65 >3% versus ≤3% | 1.14 (0.73–1.78) | 0.567 | 1.35 (0.85–2.15) | 0.205 |
| Tumor tissue | ||||
| p65 continuous | 1.02 (1.00–1.05) | 0.099 | 1.02 (0.99–1.05) | 0.216 |
| p65 >3% versus ≤3% | 1.54 (0.98–2.44) | 0.063 | 1.29 (0.80–2.07) | 0.296 |
Significant p-values given in bold.
95% CI, 95% confidence interval; HR, hazard ratio; PSA, prostate-specific antigen; pT, pathological staging of the primary tumor; RP, radical prostatectomy.